MEI Pharma http://investor.meipharma.com/ Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML) http://investor.meipharma.com/2018-01-11-Helsinn-Group-and-MEI-Pharma-Announce-that-Pracinostat-has-Received-Orphan-Drug-Designation-from-the-European-Medicines-Agency-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML Thu, 11 Jan 2018 00:00:00 -0800 http://investor.meipharma.com/2018-01-11-Helsinn-Group-and-MEI-Pharma-Announce-that-Pracinostat-has-Received-Orphan-Drug-Designation-from-the-European-Medicines-Agency-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib http://investor.meipharma.com/2018-01-08-MEI-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-CDK-Inhibitor-Voruciclib Mon, 08 Jan 2018 06:00:00 -0800 http://investor.meipharma.com/2018-01-08-MEI-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-CDK-Inhibitor-Voruciclib MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports http://investor.meipharma.com/2017-12-21-MEI-Pharma-Announces-Study-of-Clinical-Stage-Oral-CDK-Inhibitor-Voruciclib-Published-in-Nature-Scientific-Reports New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma Thu, 21 Dec 2017 06:00:00 -0800 http://investor.meipharma.com/2017-12-21-MEI-Pharma-Announces-Study-of-Clinical-Stage-Oral-CDK-Inhibitor-Voruciclib-Published-in-Nature-Scientific-Reports MEI Pharma to Host Annual Meeting of Stockholders http://investor.meipharma.com/2017-11-22-MEI-Pharma-to-Host-Annual-Meeting-of-Stockholders Live Webcast from San Diego on November 30th Wed, 22 Nov 2017 06:00:00 -0800 http://investor.meipharma.com/2017-11-22-MEI-Pharma-to-Host-Annual-Meeting-of-Stockholders MEI Pharma Reports First Quarter Fiscal Year 2018 Results http://investor.meipharma.com/2017-11-08-MEI-Pharma-Reports-First-Quarter-Fiscal-Year-2018-Results Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib Wed, 08 Nov 2017 06:00:00 -0800 http://investor.meipharma.com/2017-11-08-MEI-Pharma-Reports-First-Quarter-Fiscal-Year-2018-Results